Deutsche Bank’s Metagenomi Therapeutics MGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-5,349
Closed -$7.92K 3752
2025
Q2
$7.92K Sell
5,349
-6,372
-54% -$9.98K ﹤0.01% 3513
2025
Q1
$15.9K Buy
11,721
+10,688
+1,035% +$25.5K ﹤0.01% 3486
2024
Q4
$3.73K Buy
+1,033
New +$2.49K ﹤0.01% 3549

Other funds holding MGX

Deutsche Bank's MGX Position: Q3 2025 in Review

Deutsche Bank sold out of Metagenomi Therapeutics (MGX) in Q3 2025, closing a stake of 5,349 shares — an estimated $7.92K sold.

Deutsche Bank first reported a position in MGX in Q4 2024 and held it in 3 quarters. The position peaked at $15.9K in Q1 2025. 58 funds tracked by Wall St. Rank hold MGX as of Q3 2025.

  • Deutsche Bank reported no remaining Metagenomi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Deutsche Bank sold 5,349 Metagenomi Therapeutics shares in Q3 2025, an estimated $7.92K.
  • Deutsche Bank first reported a position in Metagenomi Therapeutics in Q4 2024 and held it in 3 quarters.
  • Deutsche Bank's Metagenomi Therapeutics position peaked at $15.9K in Q1 2025.
  • 58 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q3 2025.

Based on Deutsche Bank's 13F filing for Q3 2025, filed 13 Nov 2025.